263 related articles for article (PubMed ID: 36504883)
1. Identification of cuproptosis-related long non-coding ribonucleic acid signature as a novel prognosis model for colon cancer.
Xu R; Wu X; Du A; Zhao Q; Huang H
Am J Cancer Res; 2022; 12(11):5241-5254. PubMed ID: 36504883
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
4. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma.
Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J
Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546
[TBL] [Abstract][Full Text] [Related]
5. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
Front Oncol; 2022; 12():966920. PubMed ID: 36276132
[TBL] [Abstract][Full Text] [Related]
6. Cuproptosis-related lncRNA signature as a prognostic tool and therapeutic target in diffuse large B cell lymphoma.
Bai X; Lu F; Li S; Zhao Z; Wang N; Zhao Y; Ma G; Zhang F; Su X; Wang D; Ye J; Li P; Ji C
Sci Rep; 2024 Jun; 14(1):12926. PubMed ID: 38839842
[TBL] [Abstract][Full Text] [Related]
7. Identification and Validation of Ferroptosis-Related LncRNA Signatures as a Novel Prognostic Model for Colon Cancer.
Wu Z; Lu Z; Li L; Ma M; Long F; Wu R; Huang L; Chou J; Yang K; Zhang Y; Li X; Hu G; Zhang Y; Lin C
Front Immunol; 2021; 12():783362. PubMed ID: 35154072
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
[TBL] [Abstract][Full Text] [Related]
9. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; AbrĂ£o FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
Front Oncol; 2022; 12():988680. PubMed ID: 36203428
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
13. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma.
Wang X; Jing H; Li H
Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935
[TBL] [Abstract][Full Text] [Related]
14. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
[TBL] [Abstract][Full Text] [Related]
16. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
17. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
[TBL] [Abstract][Full Text] [Related]
18. A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer.
Xu QT; Wang ZW; Cai MY; Wei JF; Ding Q
Front Pharmacol; 2022; 13():1115608. PubMed ID: 36699089
[No Abstract] [Full Text] [Related]
19. Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.
Liu X; Zhou L; Gao M; Dong S; Hu Y; Hu C
Front Genet; 2022; 13():989646. PubMed ID: 36204323
[No Abstract] [Full Text] [Related]
20. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]